GSTM1 and B-cell chronic lymphocytic leukemia: In Figure 1, laboratory values of CLL patients at the start of obinutuzumab therapy and after immuno-chemotherapy with obinutuzumab-bendamustine are illustrated: Panel A demonstrates the leukocyte count (WBC), B hemoglobin values (Hb), C platelet count (PLT) and in D lactate dehydrogenase (LDH) levels are displayed.